Biocon Biologics on Thursday became the latest biosimilar maker to reveal a Stelara settlement with J&J.
As Johnson & Johnson's U.S. exclusivity period on its immunology blockbuster Stelara ticks away, another biosimilar player has lined up for the piece of the drug's sales pie.
Thursday, Biocon Biologics said it has inked a Stelara patent settlement with J&J. With the deal, Biocon Biologics has secured a license to allow its biosimilar to enter the U.S. market in February 2025, pending an FDA approval.
The prospect, called Bmab 1200, is currently under review at the FDA, the biosimilar maker said in a release.
As part of the deal, Biocon Biologics and J&J agreed to dismiss a pending case at the United States Patent and Trademark Office.
Biocon joins several other biosimilar players that are lining up to take on Stelara. Amgen, after inking its Stelara patent settlement in May of last year, looks set for the first Stelara biosimilar launch "no later than January 1st, 2025."
While not quite as big of a target, the Stelara situation somewhat resembles the patent cliff for AbbVie's immunology megablockbuster Humira. That drug lost its U.S. exclusivity early last year, and its full-year sales fell 32% in turn, after turning out around $20 billion a year in sales at its peak.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.